MEG3 and invasive breast carcinoma: Furthermore, we evaluated the MEG3 expression level through the TIMER database, finding that MEG3 expression was significantly lower in BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), ESCA (esophageal carcinoma), GBM (glioblastoma multiforme), KICH (kidney chromophobe), KIRP (kidney renal papillary cell carcinoma), PRAD (prostate adenocarcinoma), UCEC (uterine corpus endometrial carcinoma), than in normal controls.